Who owns VISTAGEN THERAPEUTICS ORD?
- Ticker: VTGN
- CUSIP Number: 92840h400
Tip: Access positions for across all investors
Analyze quarterly positions in Vistagen Therapeutics Ord with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vistagen Therapeutics Ord stock
Who bought or sold VISTAGEN THERAPEUTICS ORD this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BVF | 2.0M | $6.0M | 0% | Sep 2024 |
|
| Stempoint Capital | 1.8M | $3.6M | 0% | Sep 2024 |
|
| Vanguard Group | 1.8M | $6.2M | 0% | Jun 2024 |
|
| Commodore Capital | 1.6M | $4.7M | 0% | Sep 2024 |
|
| Nantahala Capital Management | 1.5M | $4.6M | 0% | Sep 2024 |
|
| Sphera Funds Management | 809k | $2.8M | 0% | Jun 2024 |
|
| Dr. Jeffrey R. Jay, M.D. | 674k | $2.0M | -56% | Sep 2024 |
|
| BlackRock | 412k | $1.2M | 100% | Sep 2024 |
|
| BlackRock | 403k | $1.4M | 16% | Jun 2024 |
|
| Citadel Advisors | 391k | $1.2M | -45% | Sep 2024 |
|
| Armistice Capital | 300k | $1.0M | -18% | Jun 2024 |
|
| Geode Capital Management | 259k | $779k | -11% | Sep 2024 |
|
| Susquehanna International | 206k | $621k | -38% | Sep 2024 |
|
| Renaissance Technologies | 191k | $574k | 194% | Sep 2024 |
|
| Goldman Sachs Group | 175k | $609k | 5% | Jun 2024 |
|
| BML Capital Management | 150k | $452k | 0% | Sep 2024 |
|
| State Street Corporation | 89k | $309k | 6% | Jun 2024 |
|
| William Blair $ Company | 89k | $266k | 0% | Sep 2024 |
|
| Two Sigma Investments | 68k | $235k | -53% | Jun 2024 |
|
| Caption Management | 55k | $164k | 100% | Sep 2024 |
|
| AdvisorShares Investments | 52k | $185k | -28% | Jun 2024 |
|
| Northern Trust | 49k | $149k | -1% | Sep 2024 |
|
| Valence8 US | 34k | $104k | 100% | Sep 2024 |
|
| American Century Companies | 30k | $91k | 0% | Sep 2024 |
|
| Charles Schwab Investment Management | 23k | $70k | 0% | Sep 2024 |
|
| Simplex Trading | 23k | $69k | 34% | Sep 2024 |
|
| Virtu Financial | 20k | $61k | 30% | Sep 2024 |
|
| Kestra Advisory Services | 20k | $60k | 100% | Sep 2024 |
|
| Jane Street | 20k | $59k | 100% | Sep 2024 |
|
| Squarepoint Ops | 11k | $40k | 100% | Jun 2024 |
|
| Advisor Group Holdings | 10k | $31k | -12% | Sep 2024 |
|
| Morgan Stanley | 5.9k | $20k | -73% | Jun 2024 |
|
| Royal Bank of Canada | 4.5k | $14k | 316% | Sep 2024 |
|
| Tower Research Capital | 2.5k | $8.6k | -28% | Jun 2024 |
|
| CWM | 2.4k | $7.0k | 0% | Sep 2024 |
|
| Bank of America Corporation | 1.8k | $5.4k | 661% | Sep 2024 |
|
| Citigroup | 1.2k | $3.7k | 40867% | Sep 2024 |
|
| BFSG | 1.0k | $3.0k | 0% | Sep 2024 |
|
| Qube Research & Technologies | 492.00 | $1.7k | 100% | Jun 2024 |
|
| SJS Investment Consulting | 100.00 | $301.000000 | 0% | Sep 2024 |
|
| Farther Finance Advisors | 81.00 | $243.996300 | 0% | Sep 2024 |
|
| Jones Financial Companies, L.L | 80.00 | $246.000000 | 0% | Sep 2024 |
|
| Fairman Group | 29.00 | $87.000000 | 0% | Sep 2024 |
|
| Jpmorgan Chase & Co | 16.00 | $48.000000 | 0% | Sep 2024 |
|
Who sold out of Vistagen Therapeutics Ord?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Barclays | Jun 2024 | 19k | $67k |
| ExodusPoint Capital Management | Mar 2024 | 18k | $97k |